Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures

Scherrer, Alexandra U; von Wyl, Viktor; Fux, Christof A; Opravil, Milos; Bucher, Heiner C; Fayet, Aurélie; Decosterd, Laurent A; Hirschel, Bernhard; Khanlari, Bettina; Yerly, Sabine; Klimkait, Thomas; Furrer, Hansjakob; Ledergerber, Bruno; Günthard, Huldrych F; Swiss HIV Cohort Study, (2010). Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. Journal of acquired immune deficiency syndromes JAIDS, 53(4), pp. 464-71. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/QAI.0b013e3181bca4ec

Full text not available from this repository. (Request a copy)

Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Fux, Christoph Andreas and Furrer, Hansjakob

ISSN:

0894-9255

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:12

Last Modified:

17 Mar 2015 19:15

Publisher DOI:

10.1097/QAI.0b013e3181bca4ec

PubMed ID:

19841590

Web of Science ID:

000275486600005

URI:

https://boris.unibe.ch/id/eprint/2710 (FactScience: 205578)

Actions (login required)

Edit item Edit item
Provide Feedback